. Author manuscript; available in PMC: 2010 Dec 1.

Published in final edited form as: Clin Cancer Res. 2009 Nov 24;15(23):7316–7321. doi: 10.1158/1078-0432.CCR-09-1263

Table 1.

Expectant Management Cohort Patients Characteristics at Diagnosis

Variable	Favorable (N = 32)	Unfavorable (N = 39)	p value^*
	Mean ± SD [Median]	Mean ± SD [Median]
Age	65.42 ± 4.37 [65.03]	64.82 ± 4.70 [64.97]	0.991
tPSA (ng/ml)	4.61 ± 2.75 [4.36]	5.35 ± 2.02 [5.53]	0.056
fPSA (ng/ml)	0.88 ± 0.59 [0.74]	0.97 ± 0.52 [0.89]	0.298
%fPSA	19.15 ± 6.36 [18.98]	18.40 ± 6.44 [18.21]	0.587
[−2] proPSA (pg/ml)	12.21 ± 7.43 [11.36]	15.00 ± 6.97 [14.24]	0.051
[−2] proPSA/%fPSA	0.65 ± 0.36 [0.55]	0.87 ± 0.44 [0.88]	0.018
PSAD (ng/ml/cm³)	0.094 ± 0.058 [0.087]	0.100 ± 0.0369 [0.100]	0.173
Prostate Volume	51.86 ± 17.50 [50.00]	57.29 ± 29.27 [50.00]	0.737
Number of Positive Core	1.19 ± 0.40 [1.00]	1.18 ± 0.39 [1.00]	0.931
Maximum %core involvement with Cancer	7.39 ± 10.13 [1.00]	8.29 ± 11.60 [1.00]	0.741
*Cancer IHC*^†
[−5/−7] proPSA %Area	11.87 ± 9.67 [9.51]	13.70 ± 9.62 [12.90]	0.371
[−5/−7] proPSA Stain Intensity	4552.54 ± 2923.61 [4055.18]	4611.47 ± 3293.73 [3119.32]	0.786
*Benign Adjacent Area IHC*^†
[−5/−7] proPSA %Area	6.88 ± 5.20 [5.38]	11.58 ± 7.08 [10.14]	0.009
[−5/−7] proPSA Stain Intensity	2418.06 ± 1606.04 [1819.76]	4104.09 ± 3033.50 [3196.52]	0.025

^†

For Cancer and Benign Adjacent Area IHC number of subjects (favorable/unfavorable) were 57 (27/30) and 54 (25/29) respectively

p values calculated using Mann-Whitney test.